No headlines found.
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
ACCESS Newswire (Fri, 1-May 9:25 AM ET)
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
ACCESS Newswire (Wed, 29-Apr 9:10 AM ET)
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
ACCESS Newswire (Thu, 23-Apr 9:05 AM ET)
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
ACCESS Newswire (Tue, 21-Apr 9:10 AM ET)
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
ACCESS Newswire (Wed, 15-Apr 9:10 AM ET)
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
ACCESS Newswire (Tue, 7-Apr 9:10 AM ET)
Lexaria to Begin New Human Clinical Study in GLP-1
ACCESS Newswire (Wed, 1-Apr 9:20 AM ET)
Lexaria's Robust Patent Portfolio Continues to Grow
ACCESS Newswire (Thu, 26-Mar 9:20 AM ET)
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
ACCESS Newswire (Tue, 24-Mar 9:15 AM ET)
Lexaria Announces New R&D Plans for 2026
ACCESS Newswire (Wed, 4-Mar 9:25 AM ET)
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Lexaria Bioscience Corp. trades on the NASDAQ stock market under the symbol LEXX.
As of May 1, 2026, LEXX stock price climbed to $0.71 with 105,924 million shares trading.
LEXX has a beta of -0.14, meaning it tends to be less sensitive to market movements. LEXX has a correlation of 0.00 to the broad based SPY ETF.
LEXX has a market cap of $17.63 million. This is considered a Sub-Micro Cap stock.
Last quarter Lexaria Bioscience Corp. reported $20,000 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-50,000 and exceeded earnings estimates by $.02.
In the last 3 years, LEXX traded as high as $6.85 and as low as $.46.
The top ETF exchange traded funds that LEXX belongs to (by Net Assets): VXF.
LEXX has underperformed the market in the last year with a price return of -42.2% while the SPY ETF gained +30.4%. LEXX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.2% and -30.9%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
LEXX support price is $.61 and resistance is $.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEXX shares will trade within this expected range on the day.
